Real-World Treatment Patterns Among Newly Diagnosed COPD Patients According to GOLD Airflow Limitation Severity Classification in a US Commercially Insured/Medicare Advantage Population

被引：1

作者：

Wallace, Anna ^{[1
]}

Zubek, Valentina ^{[1
]}

Kaila, Shuchita ^{[1
]}

Shaikh, Asif ^{[1
]}

Shinde, Mayura ^{[1
]}

Willey, Vincent ^{[1
]}

Napier, Mark ^{[1
]}

Singer, Joseph ^{[1
]}

机构：

[1] HealthCore Inc, Wilmington, DE USA

来源：

CHEST | 2017年 / 152卷 / 04期

关键词：

D O I：

10.1016/j.chest.2017.08.805

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

引用

页码：774A / 774A

页数：1

共 50 条

[1] Real-World Effectiveness of Oral Semaglutide (OS) from a US Commercially Insured and Medicare Advantage Population
Shivappa, Nitin
Swift, Caroline
Noone, Joshua
Du, Simo
Radin, Michael
Gamble, Cory
Tan, Hiangkiat
Willey, Vincent
[J]. DIABETES, 2021, 70
[2] Real-World Effectiveness of Once-Weekly Semaglutide From a US Commercially Insured and Medicare Advantage Population
Visaria, Jay
Uzoigwe, Chioma
Swift, Caroline
Dang-Tan, Tam
Paprocki, Yurek
Willey, Vincent J.
[J]. CLINICAL THERAPEUTICS, 2021, 43 (05) : 808 - 821
[3] Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD
Markus, Aniek F.
Rijnbeek, Peter R.
Kors, Jan A.
Brusselle, Guy
Burn, Edward
Prieto-Alhambra, Daniel
Verhamme, Katia
[J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 322 - 323
[4] Real-world treatment patterns of newly diagnosed patients with asthma and/or COPD
Markus, Aniek
Rijnbeek, Peter
Kors, Jan
Brusselle, Guy
Burn, Edward
Prieto-Alhambra, Daniel
Verhamme, Katia
[J]. EUROPEAN RESPIRATORY JOURNAL, 2021, 58
[5] Real-World Effectiveness of Semaglutide in Early Users from a US Commercially Insured (CI) and Medicare Advantage (MA) Population
Visaria, Jay
Dang-Tan, Tam
Petraro, Paul V.
Nepal, Bal K.
Willey, Vincent
[J]. DIABETES, 2019, 68
[6] Patterns of Comorbidity and Multimorbidity Among Patients With Multiple Sclerosis in a Large US Commercially Insured and Medicare Advantage Population
Dai, Dingwei
Sharma, Ajay
Phillips, Amy L.
Lobo, Carroline
[J]. JOURNAL OF HEALTH ECONOMICS AND OUTCOMES RESEARCH, 2022, 9 (02): : 125 - 133
[7] Treatment and Persistence With Oral Anticoagulants Among Newly Diagnosed Patients With Non-Valvular Atrial Fibrillation in a Commercially Insured and Medicare Advantage Population
Jain, Rahul
Franchino-Elder, Jessica
Fu, An-Chen
Wang, Cheng
Sander, Stephen
Tan, Hiangkiat
Kraft, Elizabeth
Willey, Vincent
[J]. CIRCULATION, 2016, 134
[8] Real-World Effectiveness of Once-Weekly Semaglutide (Sema OW) from a US Commercially Insured and Medicare Advantage Population
Visaria, Jay
Uzoigwe, Chioma
Swift, Caroline
Paprocki, Yurek M.
Willey, Vincent
[J]. DIABETES, 2020, 69
[9] Real-World Effectiveness of Once-Weekly Semaglutide (sema OW) from a US Commercially Insured and Medicare Advantage Population
Willey, Vincent
Shivappa, Nitin
Noone, Joshua
Swift, Caroline
Du, Simo
Yurek, M. Paprocki .
Tan, Hiangkiat
[J]. DIABETES, 2021, 70
[10] Treatment and persistence with oral anticoagulants among newly diagnosed patients with non-valvular atrial fibrillation: a retrospective observational study in a US commercially insured and Medicare Advantage population
Willey, Vincent
Franchino-Elder, Jessica
Fu, An-Chen
Wang, Cheng
Sander, Stephen
Tan, Hiangkiat
Kraft, Elizabeth
Jain, Rahul
[J]. BMJ OPEN, 2018, 8 (06):

← 1 2 3 4 5 →